Implementation of innovative pharmacogenetic tests into practice in Taiwan: An institutional perspective

Hsiang Yin Chen, Li Chia Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pharmacogenetic tests are proposed as a means of targeting therapy to patients such that ineffective medicine prescription and adverse events are reduced and overall benefit in terms of improved health outcomes is maximized. However, the true impact of introducing pharmacogenetic tests into clinical practice remains to be confirmed. This commentary presents some of the key requirements in developing a pharmacogenetic clinical practice model in a hospital setting. The analysis considers the need to select carefully which pharmacogenetic tests are best offered, while balancing the cost to the institution given the potential benefits to the patient population base. Drawing on our experience in Taiwan, we recommend that developing a hospital task force for pharmacogenetic testing is a recommended approach to: (1) set quality standards on how best to conduct the test, (2) provide a pro forma for interpreting results, (3) prescribe treatment appropriately according to results, and (4) design an educational program for all relevant health care team members. To further support the implementation of pharmacogenetic testing in the hospital setting, it is necessary to promote audit of clinical practice by building hospital-based registries to facilitate the collection of health care resource use and outcome data that records the clinical uptake of testing. We suggest that well-conducted economic evaluations, relevant to local practice, are essential pieces of information to guide institutional decision making on how best to develop the appropriate use of pharmacogenetic tests in clinical practice.

Original languageEnglish
Pages (from-to)502-506
Number of pages5
JournalDrug Development Research
Volume71
Issue number8
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Pharmacogenetics
Taiwan
Clinical Audit
Patient Care Team
Health Resources
Advisory Committees
Cost-Benefit Analysis
Prescriptions
Registries
Decision Making
Medicine
Delivery of Health Care
Costs and Cost Analysis
Health
Therapeutics
Population
Pharmacogenomic Testing

Keywords

  • personalized medicine
  • pharmacogenetic test
  • target therapy

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Implementation of innovative pharmacogenetic tests into practice in Taiwan : An institutional perspective. / Chen, Hsiang Yin; Chen, Li Chia.

In: Drug Development Research, Vol. 71, No. 8, 12.2010, p. 502-506.

Research output: Contribution to journalArticle

@article{995acf6f6cd54b778e8ff1f226fb9437,
title = "Implementation of innovative pharmacogenetic tests into practice in Taiwan: An institutional perspective",
abstract = "Pharmacogenetic tests are proposed as a means of targeting therapy to patients such that ineffective medicine prescription and adverse events are reduced and overall benefit in terms of improved health outcomes is maximized. However, the true impact of introducing pharmacogenetic tests into clinical practice remains to be confirmed. This commentary presents some of the key requirements in developing a pharmacogenetic clinical practice model in a hospital setting. The analysis considers the need to select carefully which pharmacogenetic tests are best offered, while balancing the cost to the institution given the potential benefits to the patient population base. Drawing on our experience in Taiwan, we recommend that developing a hospital task force for pharmacogenetic testing is a recommended approach to: (1) set quality standards on how best to conduct the test, (2) provide a pro forma for interpreting results, (3) prescribe treatment appropriately according to results, and (4) design an educational program for all relevant health care team members. To further support the implementation of pharmacogenetic testing in the hospital setting, it is necessary to promote audit of clinical practice by building hospital-based registries to facilitate the collection of health care resource use and outcome data that records the clinical uptake of testing. We suggest that well-conducted economic evaluations, relevant to local practice, are essential pieces of information to guide institutional decision making on how best to develop the appropriate use of pharmacogenetic tests in clinical practice.",
keywords = "personalized medicine, pharmacogenetic test, target therapy",
author = "Chen, {Hsiang Yin} and Chen, {Li Chia}",
year = "2010",
month = "12",
doi = "10.1002/ddr.20427",
language = "English",
volume = "71",
pages = "502--506",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Implementation of innovative pharmacogenetic tests into practice in Taiwan

T2 - An institutional perspective

AU - Chen, Hsiang Yin

AU - Chen, Li Chia

PY - 2010/12

Y1 - 2010/12

N2 - Pharmacogenetic tests are proposed as a means of targeting therapy to patients such that ineffective medicine prescription and adverse events are reduced and overall benefit in terms of improved health outcomes is maximized. However, the true impact of introducing pharmacogenetic tests into clinical practice remains to be confirmed. This commentary presents some of the key requirements in developing a pharmacogenetic clinical practice model in a hospital setting. The analysis considers the need to select carefully which pharmacogenetic tests are best offered, while balancing the cost to the institution given the potential benefits to the patient population base. Drawing on our experience in Taiwan, we recommend that developing a hospital task force for pharmacogenetic testing is a recommended approach to: (1) set quality standards on how best to conduct the test, (2) provide a pro forma for interpreting results, (3) prescribe treatment appropriately according to results, and (4) design an educational program for all relevant health care team members. To further support the implementation of pharmacogenetic testing in the hospital setting, it is necessary to promote audit of clinical practice by building hospital-based registries to facilitate the collection of health care resource use and outcome data that records the clinical uptake of testing. We suggest that well-conducted economic evaluations, relevant to local practice, are essential pieces of information to guide institutional decision making on how best to develop the appropriate use of pharmacogenetic tests in clinical practice.

AB - Pharmacogenetic tests are proposed as a means of targeting therapy to patients such that ineffective medicine prescription and adverse events are reduced and overall benefit in terms of improved health outcomes is maximized. However, the true impact of introducing pharmacogenetic tests into clinical practice remains to be confirmed. This commentary presents some of the key requirements in developing a pharmacogenetic clinical practice model in a hospital setting. The analysis considers the need to select carefully which pharmacogenetic tests are best offered, while balancing the cost to the institution given the potential benefits to the patient population base. Drawing on our experience in Taiwan, we recommend that developing a hospital task force for pharmacogenetic testing is a recommended approach to: (1) set quality standards on how best to conduct the test, (2) provide a pro forma for interpreting results, (3) prescribe treatment appropriately according to results, and (4) design an educational program for all relevant health care team members. To further support the implementation of pharmacogenetic testing in the hospital setting, it is necessary to promote audit of clinical practice by building hospital-based registries to facilitate the collection of health care resource use and outcome data that records the clinical uptake of testing. We suggest that well-conducted economic evaluations, relevant to local practice, are essential pieces of information to guide institutional decision making on how best to develop the appropriate use of pharmacogenetic tests in clinical practice.

KW - personalized medicine

KW - pharmacogenetic test

KW - target therapy

UR - http://www.scopus.com/inward/record.url?scp=78651109852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651109852&partnerID=8YFLogxK

U2 - 10.1002/ddr.20427

DO - 10.1002/ddr.20427

M3 - Article

AN - SCOPUS:78651109852

VL - 71

SP - 502

EP - 506

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 8

ER -